Loading...
Loading...
- Omnicell Inc OMCL reported second-quarter FY21 revenue growth of 36.6% year-on-year to $272.7 million, beating the analyst consensus of $268.5 million.
- The increase in revenues reflects momentum in commercial business and customer implementations and pandemic recovery.
- Product revenue increased 41.7% Y/Y to $196.9 million, while Services and other revenue rose 25% to $75.8 million.
- The non-GAAP gross margin expanded 670 bps to 51.7%, while the non-GAAP operating margin expanded by 1,060 bps to 18.3%. The non-GAAP EBITDA margin expanded 930 bps to 22.4%.
- Non-GAAP EPS of $0.97 beat the analyst consensus of $0.82.
- The company held $614.2 million in cash and equivalents. It generated $71.8 million in operating cash flow during the quarter.
- The company focuses on improving patient health outcomes and supporting its healthcare systems partners on their journey to the Autonomous Pharmacy, Chair and CEO Randall Lipps stated.
- Outlook: Omnicell sees Q3 revenue of $281 million - $286 million, above the consensus of $278.7 million. It sees non-GAAP EPS of $0.89 - $0.94 versus the consensus of $0.92.
- For 2021, it forecast total revenues of $1.100 billion to $1.115 billion, up from the prior view of $1.085 billion to $1.105 billion, versus the consensus of $1.10 billion. It sees non-GAAP EPS of $3.65 - $3.75, up from the previous $3.50 - $3.70 outlook, compared to the consensus of $3.59.
- Price action: OMCL shares traded lower by 5.06% at $140.67 in the on the last check Thursday.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in